Key points are not available for this paper at this time.
接受IV希多福韦治疗的HCT受者中有四分之一发生了大部分可逆的肾毒性。仔细选择患者和密切随访肾功能可能会减少毒性。
Stern等人(周五)研究了这个问题。
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: